U.S. Markets close in 4 hrs 45 mins

Genetron Holdings Limited (GTH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
14.12+1.11 (+8.58%)
As of 11:14AM EDT. Market open.

Genetron Holdings Limited

Building 11
1-2 Floors Zone 1, No. 8 Life Science Parkway Changping District
Beijing 102206
86 10 5090 7500

IndustryDiagnostics & Research
Full Time Employees799

Key Executives

NameTitlePayExercisedYear Born
Dr. Wei-Wu HeCo-Founder & ChairmanN/AN/A1965
Mr. Sizhen WangCo-Founder, CEO & DirectorN/AN/A1977
Dr. Hai YanCo-Founder, Chief Scientific Officer & DirectorN/AN/A1968
Mr. Ce XuChief Financial OfficerN/AN/A1982
Mr. Ying HongChief Operating OfficerN/AN/A1972
Dr. Yuchen Jiao M.D., Ph.D.Chief Technology OfficerN/AN/A1978
Dr. Yun-Fu Hu Ph.D.Chief Medical OfficerN/AN/A1963
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Corporate Governance

Genetron Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.